Increased Vancomycin Susceptibility in Mycobacteria: a New Approach To Identify Synergistic Activity against Multidrug-Resistant Mycobacteria.

Authors :: Soetaert K
Rens C
Wang XM
De Bruyn J
Lanéelle MA
Laval F
Lemassu A
Daffé M
Bifani P
Fontaine V
Lefèvre P
Source :: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2015 Aug; Vol. 59 (8), pp. 5057-60. Date of Electronic Publication: 2015 Jun 01.
Publication Year :: 2015
Abstract: Mycobacterium tuberculosis is wrapped in complex waxes, impermeable to most antibiotics. Comparing Mycobacterium bovis BCG and M. tuberculosis mutants that lack phthiocerol dimycocerosates (PDIM) and/or phenolic glycolipids with wild-type strains, we observed that glycopeptides strongly inhibited PDIM-deprived mycobacteria. Vancomycin together with a drug targeting lipid synthesis inhibited multidrug-resistant (MDR) and extensively drug-resistant (XDR) clinical isolates. Our study puts glycopeptides in the pipeline of potential antituberculosis (TB) agents and might provide a new antimycobacterial drug-screening strategy.<br /> (Copyright © 2015, American Society for Microbiology. All Rights Reserved.)

Subjects :: Cell Wall chemistry
Cell Wall drug effects
Drug Resistance, Multiple, Bacterial
Humans
Lipids biosynthesis
Microbial Sensitivity Tests
Tuberculosis, Pulmonary drug therapy
Antitubercular Agents pharmacology
Glycopeptides pharmacology
Mycobacterium bovis drug effects
Mycobacterium tuberculosis drug effects
Vancomycin pharmacology

Full Text Access

Tools